Information  X 
Enter a valid email address

Astrazeneca PLC OrdShs USD0.25 (AZN)

Date Time Source Announcement
10 Apr 2019 7:00 am
RNS
Lynparza approved in EU for the treatment of germl
09 Apr 2019 4:10 pm
EQS
Global Pharmaceuticals: 2018 industry sales
04 Apr 2019 1:30 pm
RNS
Holding(s) in Company
  1:30 pm
RNS
Holding(s) in Company
03 Apr 2019 10:00 am
RNS
Director/PDMR Shareholding
02 Apr 2019 3:00 pm
RNS
Total Voting Rights
01 Apr 2019 6:00 pm
RNS
Astrazeneca
  3:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Selumetinib gets Breakthrough Therapy Designation
29 Mar 2019 5:15 pm
RNS
Results of Placing
  7:00 am
RNS
Proposed placing of new ordinary shares
  7:00 am
RNS
AZ and Daiichi Sankyo enter collaboration in novel
27 Mar 2019 7:00 am
RNS
Forxiga approved in Japan for type-1 diabetes
25 Mar 2019 7:00 am
RNS
Forxiga approved in Europe for type-1 diabetes
18 Mar 2019 7:00 am
RNS
US FDA grants saracatinib ODD for IPF
14 Mar 2019 12:00 pm
RNS
Notice of AGM
12 Mar 2019 12:00 pm
RNS
Director/PDMR Shareholding
06 Mar 2019 7:00 am
RNS
Filing of Form 20-F with SEC
05 Mar 2019 11:00 am
RNS
Annual Financial Report
04 Mar 2019 4:04 pm
RNS
Holding(s) in Company
  4:04 pm
RNS
Holding(s) in Company
01 Mar 2019 3:00 pm
RNS
Total Voting Rights
  1:45 pm
RNS
Lynparza receives positive EU CHMP opinion
26 Feb 2019 7:00 am
RNS
Lynparza significantly delayed disease progression
25 Feb 2019 7:00 am
RNS
Brilinta's PhIII THEMIS trial met primary endpoint
14 Feb 2019 7:00 am
RNS
AstraZeneca Full-Year and Q4 2018 Results
06 Feb 2019 7:00 am
RNS
US FDA grants Fasenra Orphan Drug Designation
05 Feb 2019 7:05 am
RNS
US FDA grants Breakthrough Therapy Designation
  7:00 am
RNS
EMA grants PRIME eligibility for MEDI8897
01 Feb 2019 3:00 pm
RNS
Total Voting Rights
  1:17 pm
RNS
Forxiga receives positive EU CHMP opinion
25 Jan 2019 2:00 pm
RNS
Completion of divestment of US Synagis rights
07 Jan 2019 1:00 pm
RNS
AstraZeneca announces organisational changes
02 Jan 2019 3:00 pm
RNS
Total Voting Rights
20 Dec 2018 1:47 pm
RNS
Bevespi Aerosphere approved in the EU for COPD
  7:05 am
RNS
Lynparza meets primary endpoint in SOLO-3 trial
  7:00 am
RNS
Phase III ROCKIES and OLYMPUS roxadustat trials
19 Dec 2018 6:31 pm
RNS
FDA approves Lynparza as 1L maintenance therapy
18 Dec 2018 9:09 am
RNS
Roxadustat approved in China for the treatment of
14 Dec 2018 7:00 am
RNS
Directorate Change
07 Dec 2018 7:00 am
RNS
Update on the Phase III EAGLE trial of Imfinzi
06 Dec 2018 7:00 am
RNS
Divestment of rights to Covis completed
04 Dec 2018 3:00 pm
RNS
Director/PDMR Shareholding
03 Dec 2018 4:00 pm
RNS
Block listing Interim Review
  4:00 pm
RNS
Total Voting Rights
  7:00 am
RNS
Gr?nenthal Agreement for Nexium, Vimovo Completed
26 Nov 2018 7:00 am
RNS
US FDA grants Fasenra ODD for EGPA
16 Nov 2018 7:00 am
RNS
AstraZeneca provides update on Phase III MYSTIC
13 Nov 2018 7:00 am
RNS
AstraZeneca to divest US Synagis rights to Sobi
12 Nov 2018 7:05 am
RNS
US FDA accepts regulatory submission for Lynparza
  7:00 am
RNS
Farxiga significantly reduced hospitalisation for
08 Nov 2018 7:00 am
RNS
AZN: Year-to-Date and Q3 2018 Results
06 Nov 2018 7:00 am
RNS
Divestment of rights to Covis Pharma
01 Nov 2018 3:00 pm
RNS
Total Voting Rights
31 Oct 2018 9:45 am
RNS
Additional financial information-Gr?nenthal deal
30 Oct 2018 7:00 am
RNS
Gr?nenthal Agreement for rights to Nexium, Vimovo
23 Oct 2018 7:00 am
RNS
AstraZeneca Extends Innate Pharma Collaboration
22 Oct 2018 7:00 am
RNS
Lynparza shows 70% reduction in PFS ovarian cancer
19 Oct 2018 1:09 pm
RNS
CHMP positive opinion Bevespi Aerosphere
16 Oct 2018 7:00 am
RNS
FDA Orphan Drug for Lynparza in pancreatic cancer
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t